Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06952426 · ClinicalTrials.gov registry record

A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US

A clinical trial of Immunoglobulin A Nephropathy, sponsored by Novartis Pharmaceuticals.

Recruiting
Registry status
300
Enrollment target
1
Study location

NCT06952426 is a study of Immunoglobulin A Nephropathy that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 300 participants, roughly in line with the 281-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06952426, a study of Immunoglobulin A Nephropathy, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.

RECRUITING
Registry status
300 participants
Enrollment target
1
Study location

Study Summary

The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (HRQoL) experienced by Immunoglobulin A nephropathy (IgAN) patients and their caregivers.

Conditions Studied

Immunoglobulin A Nephropathy

Interventions

  • OTHER No intervention
  • OTHER Other treatment
  • OTHER Iptacopan
  • OTHER Atrasentan

Study Locations (1)

Massachusetts

  • Novartis Investigational site - Boston

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2025-03-04
Est. Completion 2025-06-30

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06952426

The ClinicalTrials.gov registry entry for NCT06952426 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 281-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Immunoglobulin A Nephropathy appearing as the primary indexed condition, and to 4 interventions - of which No intervention is the first listed.

NCT06952426 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06952426 about?

NCT06952426 is a clinical study titled "A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US". The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (HRQoL) experienced by Immunoglobulin A nephropathy (IgAN) patients and their caregivers.

What is the current status of trial NCT06952426?

This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2025-03-04. Estimated completion is 2025-06-30.

What conditions does trial NCT06952426 study?

This clinical trial studies the following conditions: Immunoglobulin A Nephropathy.

What interventions are being tested in trial NCT06952426?

The interventions under investigation include: No intervention (OTHER), Other treatment (OTHER), Iptacopan (OTHER), Atrasentan (OTHER).

Who is sponsoring clinical trial NCT06952426?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06952426 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Immunoglobulin A Nephropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Immunoglobulin A Nephropathy

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.